CDK4/6 inhibitor combinations have demonstrated significantly extended progression-free survival in patients who received no prior systemic therapy for advanced disease in the MONALEESA-2 [16] and PALOMA-2 [22] trials, highlighting the utility of this treatment strategy in the first-line setting for advanced HR+, HER2− breast cancer. This evidence concerns the gene ERBB2 and breast cancer.